Hangzhou Alltest Biotech (SH:688606) Zheng Quan Zhi Xing·2025-06-30 16:11Core Viewpoint - The company, Hangzhou Aotai Biotechnology Co., Ltd., is utilizing temporarily idle raised funds for cash management to enhance fund efficiency and returns for shareholders while ensuring that it does not affect the progress of investment projects [1][8]. Fundraising Overview - The company raised a total of RMB 1,804,545,000 through its initial public offering, with a net amount of RMB 1,643,266,906.25 after deducting issuance costs [1]. - The funds are stored in a special account approved by the board of directors, and a tripartite supervision agreement has been signed with the sponsor and the commercial bank [1]. Investment Projects - The raised funds are planned to be invested in projects including the construction of a production and R&D center for in vitro diagnostic reagents, with a total investment of RMB 146,059,100 [2][3]. Cash Management Details - The company plans to use up to RMB 480 million of temporarily idle funds for cash management, investing in low-risk, highly liquid products with a maturity of no more than 12 months [5][6]. - The cash management products include but are not limited to agreement deposits, structured deposits, and large certificates of deposit [5]. Approval Process - The board of directors and the supervisory board have approved the cash management plan, which does not require shareholder approval [7][8]. - The company will ensure compliance with relevant regulations and maintain transparency in information disclosure [5][8]. Impact on Operations - The cash management strategy is designed to improve fund efficiency without impacting the company's daily operations or the progress of investment projects [6][8].